Download CURRICULUM VITAE

CURRICULUM VITAE
BONNIE E. GOULD ROTHBERG, MD, PhD, MPH
Address: 215 Uncas Point Road
Guilford, CT 06437
(203) 453-2966 (home)
(203) 980-2394 (cell)
[email protected]
Biographical Data:
Birthdate: November 15, 1968
Birthplace: Montreal, Canada
Citizenship: US & Canada
ACADEMIC TRAINING

DOCTOR OF PHILOSOPHY, Chronic Disease Epidemiology, Qualifying Exams Passed With Distinction
Yale University Graduate School of Arts and Sciences, New Haven, CT, 2009
Dissertation committee chairman: David L. Rimm, MD, PhD
Masters’ of Philosophy awarded en route May 2007

MASTERS OF PUBLIC HEALTH, Chronic Disease Epidemiology.
Yale University School of Medicine, New Haven, CT. 2005.
Advisors: Michael B. Bracken, MPH PhD, Elizabeth B. Claus, PhD MD

DOCTOR OF MEDICINE.
Yale University School of Medicine, New Haven, CT. 1994.
Advisor: John Harley Warner, PhD

BACHELOR OF ARTS, Summa Cum Laude in Biological Sciences, with Distinction in All Subjects.
Cornell University College of Arts and Sciences, Ithaca, NY. 1990.
Advisor: Charles F. Aquadro, PhD
POST-GRADUATE MEDICAL TRAINING

RESIDENT, INTERNAL MEDICINE-TRADITIONAL PROGRAM
Yale-New Haven Hospital, New Haven, CT
06/2013-06/2016

RESIDENT, INTERNAL MEDICINE/PRIMARY CARE
Yale University Affiliated Hospitals, Waterbury, CT
06/1996-01/1997

INTERN, INTERNAL MEDICINE
Yale-New Haven Hospital, New Haven, CT
01/1996-06/1996

RESIDENT, OBSTETRICS AND GYNECOLOGY
Yale-New Haven Hospital, New Haven, CT
06/1994-08/1995
PROFESSIONAL CERTIFICATION







American Board of Internal Medicine
Connecticut State Medical License #036031
United States DEA license for controlled substances (classes 2-5) #BG5997929
Connecticut State DEA license for controlled substances (classes 2-5) #26292
USMLE Step III (Score = 204)
USMLE Step II (Score = 209)
USMLE Step I (Score = 240, 98th %ile)
Bonnie E. Gould Rothberg, MD, PhD, MPH
1
Passed:
Issued:
Issued:
Issued:
Passed:
Passed:
Passed:
Oct. 17th, 2016
May 23rd, 1997
Aug. 24th, 1998
Mar. 1st, 1998
Dec. 1994
Mar. 1994
May, 1992
5/4/2017
OCCUPATIONAL RECORD
Yale University School of Medicine
04/2017-present
New Haven, CT
03/2013-present
07/2011-present
07/2011-present
07/2010-07/2011
01/2009-06/2010
The Rothberg Institute for Childhood Diseases 07/2002-06/2006
Guilford, CT
CuraGen Corporation
New Haven, CT
Oncology Hospitalist – Smilow Cancer
Hospital Oncology Extended Care Unit
Assistant Professor – Pathology (Secondary
Appointment)
Assistant Professor – Epidemiology and
Public Health (Secondary Appointment)
Assistant Professor – Internal Medicine
(Medical Oncology)
Associate Research Scientist − Pathology
Postdoctoral Fellow − Pathology
07/2002-04/2003
Director of Clinical Development
Acting Scientific Director
02/2001-07/2002
01/1999-02/2001
01/1997-12/1998
Group Leader-Medical Affairs
Group Leader-Pharmacogenomics
Medical Scientist-Gene Discovery
HONORS AND AWARDS









Third prize, LAM/TSC seminar series 2011 live/virtual poster session competition, Boston, MA, March 24 th, 2011.
Anna Fuller Fellowship for Cancer Research. 2006-2007 academic year.
Dean’s Prize for Outstanding Master’s Thesis. Yale University Department of Epidemiology and Public Health.
2005.
NIH Cancer Education Grant/Yale Cancer Center Medical Student Research Training Fellowship. 2004.
Phi Beta Kappa. Cornell University. 1990.
Mortar Board Honor Society. Cornell University. 1989.
Golden Key Honor Society. Cornell University. 1989.
Montreal Board of Trade: Silver Medal-Maths & Sciences Division-Montreal Outstanding Student Competition.
1986.
Rensselaer Polytechnic Institute Award for Maths and Science. 1985.
PROFESSIONAL EXPERIENCE
Yale University School of Medicine (01/2009-present):


ASSISTANT PROFESSOR OF MEDICINE (MEDICAL ONCOLOGY), EPIDEMIOLOGY AND
PATHOLOGY, 07/2011-PRESENT
- Managing an independent, laboratory-based research program in Molecular Cancer Epidemiology.
- Founding and ongoing Medical Director for The Yale Lung and Gastrointestinal Cancer Biorepositories, resources
that combine biospecimen best practices with robust clinicoepidemiologic annotations to create prospective
cohorts of incident cases of early-stage lung and gastrointestinal cancers being evaluated and treated at the Yale
Cancer Center (Total enrollments of 600 and 500 patients, respectively, through October 31 st, 2015).
- Building novel bioinformatics platforms for the analysis of Ion Torrent next-generation DNA sequencing data
including: 1) a front-end quality-control platform for individual run triage prior to analysis, 2) methods for
optimizing tumor somatic variant calling and facilitating their visualization by non-computationally-focused
physicians and scientists and 3) integration of RNA-Seq transcriptome data with whole exome sequence analysis.
- Evaluating modifiable lifestyle choices as prognostic determinants in intermediate/advanced stage resected
localized cutaneous melanoma and early-stage lung cancer.
- Evaluating tumor somatic mutations in the prognosis of completely resected, early-stage lung adenocarcinomas.
- Evaluating germline genetic variation in the prognosis of intermediate/advanced stage resected localized cutaneous
melanoma.
- Integrating whole exome sequencing with RNA-Seq transcriptome data to characterize subclasses of pancreatic
neuroendocrine tumors.
ASSOCIATE RESEARCH SCIENTIST, 07/2010-07/2011
POST-DOCTORAL RESEARCH FELLOW, 01/2009-06/2010
Laboratory of Dr. David L. Rimm, Department of Pathology
Bonnie E. Gould Rothberg, MD, PhD, MPH
2
5/4/2017
- Conducted research in cutaneous melanoma with the goal of developing immunohistochemistry-based multimarker molecular classifiers of prognosis that, when combined with established clinicopathologic variables in
multivariable survival analyses, increase the ability to triage Stage II melanoma patients most at risk for
developing metastatic disease.
-Conducted research into the mechanisms of benign metastasis of kidney angiomyolipomas, funded by the LAM
Treatment Alliance.
The Rothberg Institute for Childhood Diseases (07/2002-06/2006):


DIRECTOR OF CLINICAL DEVELOPMENT
07/2002-06/2006
-Responsible for the clinical development of all novel compounds developed either at TRI or in conjunction with
collaborating institutions for the treatment of Tuberous Sclerosis clinical manifestations.
-Managed and coordinated all genomic studies comparing tissues derived from TSC hamartomas to appropriate
normal control tissue and drive antibody therapeutic and small molecule drug target selection based on these
comparative expression patterns.
-Facilitated ‘Ask Dr. Bonnie’, an online medical clinic where patients with Tuberous Sclerosis and their caregivers
can ask questions and seek medical referrals for medical issues related to their disease (Through 01/2006).
(www.childhooddiseases.org/cgi-tsc/ultimatebb.cgi).
ACTING SCIENTIFIC DIRECTOR
07/2002-04/2003
-Managed and coordinated all Institute cell-based R&D programs including the generation of immortalized primary
cell lines derived from patient kidney angiomyolipoma cells.
-Coordinated the research efforts of academic collaborators funded by the Rothberg Courage Fund, co-administered
by the Tuberous Sclerosis Alliance and The Rothberg Institute.
-Headed collaborations with Pharmaceutical and Biotechnology partners to assay lead compounds in cellular and
animal models of Tuberous Sclerosis
 CuraGen Corporation: Novel anti-PDGF-D monoclonal antibody
 Ariad Corporation: Novel orally administered rapamycin analogs
CuraGen Corporation (01/1997-07/2002):


GROUP LEADER-MEDICAL AFFAIRS
02/2001-07/2002
-Established and coordinated preclinical and clinical pharmacogenomics and surrogate biomarker programs
(expression pharmacogenomics and pharmacogenetics) to support all CuraGen protein therapeutics and
monoclonal antibodies in development.
-Clinical Development Strategy and Clinical Trial Protocol development for Phase I and Phase II programs in
inflammatory bowel diseases & oral mucositis.
-Served as Clinical Liaison for Disease Program efforts in Metabolic Diseases, Oncologic Diseases, Inflammatory
and Autoimmune Diseases and Central Nervous System Diseases.
GROUP LEADER-PHARMACOGENOMICS
01/1999-02/2001
-Scientific Lead on the acquisition of $124 million Pharmacogenomics/Toxicogenomics collaboration with Bayer
Pharmaceuticals AG on 01/12/01.
-Scientific Lead on the acquisition and execution of $3.75 million Pharmacogenomics collaboration with Ono
Pharmaceuticals, 06/00-06/01.
-Scientific Lead on execution of Pharmacogenomics studies as part of the 6 F.T.E. Roche Pharmaceuticals
collaboration, 01/99-12/00.
-Scientific and Project Lead on execution of the Human Apolipoprotein E transgenic mouse model of Alzheimer’s
Disease study in collaboration with Ann Saunders (Duke University) and Allen Roses, Vice President and
Worldwide Director, Genetics and Co-Chair, Exploratory Discovery Board, Glaxo Wellcome Research and
Development.
-Built CuraGen’s Pharmacogenomics program from 1 employee in 01/98 to 14 employees trained in Expression
Pharmacogenomics and Pharmacogenetics in 02/01.
-Created an expression pharmacogenomics in vivo reference drug treatment sample repository that included 5350
individual rat organ samples representing over 175 drug treatments and vehicle controls (2 dose/time points each).
-Maintained an expression pharmacogenomics in vitro sample repository that included 1050 lysate samples from 14
cell lines treated with a panel of 30 protein therapeutics.
-Executed pilot expression toxicogenomics studies to uncover molecular markers of failed drugs including
troglitazone, dexfenfluramine, bromfenac and benoxaprofen.
-Established, in collaboration with the Bioinformatics Department, the web-based GeneScape Pharmacogenomics
data analysis package for extracting toxicogenomic markers and tracking their behavior across matrices of
dose/time courses for candidate drugs.
Bonnie E. Gould Rothberg, MD, PhD, MPH
3
5/4/2017

MEDICAL SCIENTIST-GENE DISCOVERY
01/1997-12/1998
-Project Leader on collaboration pilots for Genentech, Glaxo-Wellcome and Wyeth-Ayerst
-Project Leader for all academic collaborative efforts in the fields of Oncology and Vesicle Trafficking
-Discovery liaison for Bioinformatics during the construction of Workflow and Discovery Processes for GeneScape
GeneCalling project management.
SERVICE/COMMITTEES: YALE SCHOOL OF MEDICINE
Yale School of Medicine Curriculum Redesign: Basic and Clinical Sciences Master Courses Design Committee
(10/2012-12/2013)
 Contributed towards defining the longitudinal Epidemiology and Public Health thread that will wind through each of
the 8 Master Courses and define the associated pedagogy to be introduced during the first 18 months of the redesigned
Yale Medical School curriculum.
Clinical Research Data Repository Working Group (09/2012-12/2012)
 Contributed to discussions for the process of automating clinical data abstraction from the Electronic Medical Record
by providing concrete examples of data fields useful for longitudinal analysis of survivorship and how my group
extracts these fields manually from the EMR.
Health Promotion and Disease Prevention Goals Committee – Yale School of Medicine Curriculum Redesign
(05/2012-07/2012)
 Contributed towards defining the overarching goals and highest level of competencies relating to concepts of Health
Promotion and Disease Prevention that Yale Medical Students are expected to master.
SERVICE/COMMITTEES: EXTERNAL ORGANIZATIONS
Board of Directors, Directorships

Tuberous Sclerosis Alliance, Member of the Board of Directors. 2000-2006.
Professional/Scientific Advisory Boards

Member of the External Advisory Board, Tuberous Sclerosis Natural History Project, Tuberous Sclerosis Alliance.
2011-present
Meeting Planning Committees

2013 Tuberous Sclerosis International Conference; Organizing Committee Member. 2012-2013
JOURNAL EDITOR/ASSOCIATE EDITOR/PEER REVIEW
Peer Review Groups
1. American College of Physicians Medical Knowledge and Self-Assessment Program (MKSAP) 18, Section of General
Internal Medicine.
Editor/Associate Editor
World Journal of Gastroenterological Physiology (Associate Editor)
Reviewer
Lancet Oncology
British Journal of Dermatology
BMC Cancer
Cancer
Cancer Immunology Research
PLOS One
American Journal of Epidemiology
PROFESSIONAL SOCIETY MEMBERSHIPS










American Society for Clinical Oncology. 2014-present
American College of Physicians. 2013-present
International Society for Biological and Environmental Repositories. 2012-2015.
Southwestern Oncology Group (SWOG). 2012-present.
Society for Melanoma Research. 2012-2016
Society for Epidemiologic Research. 2006-present.
American Association of Cancer Research. 2006-present.
Drug Information Association. 2003-2006.
American Association of Pharmaceutical Scientists. 1999-2006.
American Medical Association. 1991-present.
Bonnie E. Gould Rothberg, MD, PhD, MPH
4
5/4/2017
GRANTS/FUNDING AWARDS
NIH 1R01 CA204120-01 (S. Ma, PI)
07/01/16-06/30/20 ($1,250,000)
Novel methods for identifying genetic interactions in cancer prognosis
Goals: To develop novel marginal and joint analysis methods that are robust to data contamination and model misspecification for identifying important interactions.
Role: co-Investigator
Bonnie E. Gould Rothberg, MD, PhD, MPH
5
5/4/2017
DOD LC140549 (K. Anderson, PI)
09/01/15-08/31/16 ($100,000)
Exploring APOBEC3B as a Novel Target for Squamous Cell Lung Cancer
Goals: To explore the novel hypothesis that APOBEC3B, a DNA cytosine deaminase, can act as a proto-oncogene by
introducing mutations in key regulatory proteins such as TP53. This project will seek to understand the spectrum of mutation
patterns found in APOBEC3B-dysregulated squamous cell carcinomas and how they impact the progression and phenotype
of lung cancers with the goal of identifying innovative strategies for prevention and treatment for early and/or localized lung
cancer.
Role: co-Investigator
NIH 1P50 CA196530-01 (R.S. Herbst, PI)
08/01/15-07/31/20 ($11.5 million; $1,250,000 to Core)
Yale SPORE in Lung Cancer Core C: The Biospecimen, Pathology and Genomics Core
Goals: To support the Yale SPORE in Lung Cancer by: 1) collecting, storing and distributing human biospecimens with
complete clinical, pathological and demographic annotation, 2) to conduct or assist in molecular pathology analyses of
biospecimens.
Role: Core co-Director
Yale Cancer Center Pilot Fund Award (B. Cartmel, PI)
04/01/15-03/31/16 ($48,326)
E-cigarette use in early-stage lung cancer survivors – Prevalence, knowledge and attitudes
Goals: To understand the prevalence and patterns of e-cigarette use in a population of early-stage lung cancer survivors
following curative-intent complete resection.
Role: co-Investigator
NIH 1R21 CA191383 (S. Ma, PI)
12/24/14-12/31/17 ($261,000)
Penalization methods for identifying Gene-Environment interactions and applications to melanoma and other tumor
types
Goals: To develop novel statistical methods for the identification of specific genetic/molecular events extracted from
large ‘omic-level datasets that are significantly associated with clinical parameters with the future potential for their
translation into the clinic.
Role: co-Investigator
RE Leet and CG Patterson Trust Awards (B.E. Gould Rothberg, PI)
02/01/14-12/31/15 ($100,000)
Germline Genetic Variation in T2a-T4b cutaneous melanoma prognosis
Goals: To determine the prognostic impact of germline genetic variation in intermediate-thickness and thick localized or
micrometastatic cutaneous melanomas treated with curative-intent complete resection.
Role: Principal Investigator
American Cancer Society #IRG 58-012-56 (B.E. Gould Rothberg, PI)
12/16/13-02/15/15 ($20,000)
Genetic Variation in T2a-T4b cutaneous melanoma prognosis
Goals: To determine the prognostic impact of somatic mutations and germline genetic variation in intermediate-thickness
and thick localized or micrometastatic cutaneous melanomas treated with curative-intent complete resection.
Role: Principal Investigator
Section of Medical Oncology Junior Faculty Pilot Grant (B.E. Gould Rothberg, PI) 10/01/12-03/31/14 ($50,000)
Predicting lung cancer molecular subtypes using [18F]-FDG-PET-CT scan imaging biomarkers
Goals: To determine whether morphologic or metabolic-based parameters extracted from non-contrast
CT and [18F]-FDG PET scan images can distinguish among major subclasses of lung adenocarcinoma tumors as determined
by either somatic mutations or transcriptome analysis.
Role: Principal Investigator
Yale Gastrointestinal Cancer Program/Hixon Gift (H. Hochster, PI)
03/15/12-present ($100,000/year)
The Yale Gastrointestinal Cancer Biorepository
Goals: To build a biorepository of upper and lower GI cancer specimens complemented with comprehensive, clinical and
lifestyle annotations deriving from incident GI cancer patients presenting to the Yale Cancer Center GI Oncology Program
for first-line treatment of their disease.
Role: Biobank Medical Director
Bonnie E. Gould Rothberg, MD, PhD, MPH
6
5/4/2017
Yale Thoracic Oncology Program (L. Tanoue, PI)
09/01/10-06/30/15 ($270,000)
The Yale Lung Cancer Biorepository
Goals: To build a biorepository of lung cancer specimens complemented with comprehensive, clinical and lifestyle
annotations deriving from incident lung cancer patients presenting to the Yale Cancer Center Thoracic Oncology Program for
first-line treatment of their disease.
Role: Biobank Medical Director
NIH 1K08CA151645-01 (B.E. Gould Rothberg, PI)
07/01/10-06/30/15 ($425,000)
Prognostic Markers in Metastatic Melanoma
Goals: To build an integrated prognostic model for time to death from metastatic melanoma from clinicopathologic variables,
germline genetic variation, and tumor-based somatic mutations and candidate protein expression in a retrospective discovery
cohort of patients treated at Yale-New Haven Hospital during 1959-1994 and validate this model in an independent
retrospective cohort of patients with metastatic melanoma resected at Yale-New Haven Hospital during 1995-2005.
Role: Principal Investigator
LAM Treatment Alliance (BE Gould Rothberg, PI)
12/01/09-09/30/11 ($65,000)
Mechanisms of Benign Metastasis in Kidney Angiomyolipomas
Goals: To examine the distribution of proteins previously associated with the metastasis of primary melanoma to the lung on
neural crest-derived kidney angiomyolipomas (AMLs) and lung lymphangioleiomyomatosis (LAM) tissue to identify
potential candidates that mediate metastasis of kidney AML cells to the lung.
Role: Principal Investigator
PUBLICATIONS
1.
Rubinstein JC, Han G, Jackson L, Bulloch K, Ariyan S, Narayan D, Gould Rothberg B, and Han D. 2016. Regression in
thin melanoma is associated with nodal recurrence after a negative sentinel node biopsy. Cancer Medicine Sept. 27th
epub (doi: 10.1002/cam4.922). PMID: 27671840.
2.
Bello DM, Han G, Jackcson L, Bulloch K, Ariyan S, Narayan D, Gould Rothberg B and Han D. 2016. The prognostic
significance of sentinel lymph node status for patients with thick melanoma. Annals of Surgical Oncology Aug 15th epub
(doi: 10.1245/s10434-016-5502-y). PMID 27527717.
3.
Srisuttiyakorn C, Bulloch K, Rodic N, Bosenberg M, Ariyan S, Narayan D, Gould Rothberg BE and Galan A. 2016.
Intratumoral multinucleated giant cells are not a prognostic pathologic feature in cutaneous melanoma. Journal of
Cutaneous Pathology June 1st epub (doi: 10.1111/cup.12750). PMID: 27246995.
4.
Bellizzi KM and Gould Rothberg BE. 2016. Survivorship care for older adults with cancer: the role of primary care
physicians and utility of care plans as a communication tool. In: Handbook of Geriatric Oncology. Kroc-Grodzicki M
and Tew WP eds. In press.
5.
Jiang Y, Shi X, Zhao Q, Krauthammer M, Gould Rothberg BE, and Ma S. 2016. Integrated analysis of
multidimensional omics data on cutaneous melanoma prognosis. Genomics 107(6): 223-230. PMID: 27141884, PMCID:
PMC4893887.
6.
Gould Rothberg BE and Rothberg JM. 2015. Massively parallel (“Next-generation”) DNA sequencing. 2015. Clinical
Chemistry 61(7): 997-998.
7.
Gould Rothberg BE, Bulloch KJ, Fine JA, Barnhill RL and Berwick M. 2014. Red meat and fruit intake is prognostic
among patients with localized cutaneous melanomas more than 1 mm thick. Cancer Epidemiology 38(5): 599-607.
8.
Dhamija A, Rosen JE, Dhamija A, Gould Rothberg BE, Kim AW, Detterbeck FC and Boffa DJ. 2014. Learning curve
to lymph node resection in minimally invasive esophagectomy for cancer. Innovations (Philadelphia): 9(4): 286-291.
9.
Gould Rothberg BE and Rimm DL. 2014. Construction and analysis of multi-parameter models for the prediction of
recurrence in melanoma. Methods in Molecular Biology 1102: 227-258.
10. Viray H, Bradley WR, Schalper KA, Rimm DL and Gould Rothberg BE. 2013. Marginal and joint distributions of
S100, HMB45 and Melan-A across a large series of cutaneous melanomas. Archives of Pathology and Laboratory
Medicine 137(8): 1063-1073.
Bonnie E. Gould Rothberg, MD, PhD, MPH
7
5/4/2017
11. Damsky WE, Curley DP, Santhankrishnan M, Rosenbaum LE, Platt JT, Gould Rothberg BE, Taketo MM, Dankort D,
Rimm DL, McMahon M, & Bosenberg M. 2011. β-catenin signaling controls metastasis in BRAF-activated PTENdeficient melanomas. Cancer Cell 20(6): 741-754.
12. Dimou A, Agarwal S, Anagnostou V, Viray H, Christensen S, Gould Rothberg B, Zolota V, Syrigos K & Rimm DL.
2011. Standardization of epidermal growth factor receptor (EGFR) measurement by quantitative immunofluorescence
and impact on antibody-based mutation detection in non-small cell lung cancer. American Journal of Pathology 179(2):
580-589.
13. Gould Rothberg BE, Magriples U, Kershaw TS, Rising SS & Ickovics JR. 2011. Gestational weight gain and
subsequent post-partum weight loss among young, low-income ethnic minority women. American Journal of Obstetrics
and Gynecology 204: 52 (e1-e11).
14. Gould Rothberg BE & Rimm DL. 2010. Biomarkers: The useful and the not so useful. An assessment of molecular
prognostic markers for cutaneous melanoma. Journal of Investigative Dermatology 130: 1971-1987
15. Gould Rothberg BE, Berger AJ, Molinaro AM, Subtil A, Krauthammer MO, Camp RL, Bradley WR, Ariyan S, Kluger
HM, & Rimm DL. 2009. Identification of a melanoma prognostic model using tissue microarrays and genetic
algorithms. Journal of Clinical Oncology 27: 5772-5780.
16. Chien AJ, Moore EC, Lonsdorf AS, Kulikauskas RM, Gould Rothberg B, Berger AJ, Major MB, Hwang ST, Rimm
DL, & Moon RT. 2009. Activated Wnt/β-catenin in melanoma is associated with decreased proliferation in patient
tumors and a murine melanoma model. Proceedings of the National Academy of Science 106: 1193-1198.
17. Lazova R, Gould Rothberg BE, Rimm DL, & Scott G. 2009. The semaphorin 7A receptor plexin C1 is lost during
melanoma metastasis. American Journal of Dermatopathology 31: 177-181.
18. Gould Rothberg BE, Bracken MB, & Rimm DL. 2009. Tissue biomarkers for prognosis in cutaneous melanoma: A
systematic review and meta-analysis. Journal of the National Cancer Institute 101: 452-474.
19. Gould Rothberg BE, Moeder CB, Kluger H, Halaban R, Elder DE, Murphy GF, Lazar A, Prieto V, McDivitt Duncan L
& Rimm DL. 2008. Nuclear to non-nuclear pmel17/gp100 expression (HMB45 staining) as a discriminator between
benign and malignant melanocytic lesions. Modern Pathology 21: 1121-1129.
20. Kreizenbeck GM, Berger AJ, Subtil A, Rimm DL, & Gould Rothberg BE. 2008. Prognostic significance of cadherinbased adhesion molecules in cutaneous malignant melanoma. Cancer Epidemiology Biomarkers and Prevention 17: 949958.
21. McCarthy MM, Pick E, Kluger Y, Gould-Rothberg B, Lazova R, Camp RL, Rimm DL, & Kluger HM. 2008. HSP90 as
a marker of progression in melanoma. Annals of Oncology 19: 590-594.
22. Gould Rothberg BE & Bracken MB. 2006. E-cadherin immunohistochemical expression as a prognostic factor in
infiltrating ductal carcinoma of the breast: a systematic review and meta-analysis. Breast Cancer Research and
Treatment 100: 139-148. e-pub DOI 10.1007/s10549-006-9248-2.
23. Gould Rothberg BE, Grooms MC, & Dharnidharka VR. 2006. Rapid growth of a kidney angiomyolipoma following
initiation of oral contraceptive therapy. Obstetrics and Gynecology 108: 734-736.
24. de Vries P, Humphrey A, McCartney D, Prather P, Bolton P, Hunt A, and the TSC Behaviour Consensus Panel. 2005.
Consensus clinical guidelines for the assessment of cognitive and behavioural problems in Tuberous Sclerosis. European
Child and Adolescent Psychiatry 14: 183-190.
25. Gould Rothberg BE, Peña CEA, & Rothberg JM. 2005. Chapter 4: A systems biology approach to target identification
and validation for human chronic disease drug discovery. In: Modern Biopharmaceuticals – Design, Development and
Optimization. J. Knäblein, ed., Wiley-VCH Verlag. Weinheim, Germany. pp 99-125.
26. Gould Rothberg BE. 2003. Re: Hemorrhagic angiomyolipoma and Tuberous Sclerosis Complex: a case report.
Recognizing the needs of a growing population of adults with Tuberous Sclerosis Complex. Connecticut Medicine 67:
313-314.
Bonnie E. Gould Rothberg, MD, PhD, MPH
8
5/4/2017
27. Onda H, Crino PB, Zhang H, Murphey RD, Rastelli L, Gould Rothberg BE, & Kwiatkowski DJ. 2002. TSC2 null
murine neuroepithelial cells are a model for human tuber giant cells and show activation of an mTOR pathway.
Molecular and Cellular Neuroscience 21: 561-574.
28. Gould Rothberg BE. 2001. Mapping a role for SNPs in drug development (News and Views). Nature Biotechnology
19: 209-211.
29. Gould Rothberg BE. 2001. The use of animal models in expression pharmacogenomic analyses. The
Pharmacogenomics Journal 1: 48-58.
30. Herrmann JL, Rastelli L, Burgess CE, Gould Rothberg BE, Rothberg JM, & Shimkets RA. 2001. Implications of
oncogenomics for cancer research and clinical oncology. The Cancer Journal 7: 40-51.
31. Gould Rothberg BE, Sundseth SS, DiPippo VA, Brown PJ, Winegar DA, Gottshalk WK, Shenoy SG & Rothberg JM.
2001. The characterization of PPAR ligand drug action in an in vivo model by comprehensive differential gene
expression profiling. Functional and Integrative Genomics 1: 294-304.
32. Rininger JA, DiPippo VA, & Gould Rothberg BE. 2000. Differential gene expression technologies for identifying
surrogate markers of drug efficacy and toxicity. Drug Discovery Today 5: 560-568.
33. Basson MD, Liu YW, Hanly AM, Emenaker NJ, Shenoy SG, & Gould Rothberg BE. 2000. Identification and
comparative analysis of human colonocyte short-chain fatty acid response genes. Journal of Gastrointestinal Surgery 4:
501-512.
34. Gould Rothberg BE, Ramesh TM & Burgess CE. 2000. Integrating expression-based drug response and SNP-based
pharmacogenetic strategies into a single comprehensive pharmacogenomics program. Drug Development Research 49:
54-64.
35. Shimkets RA, Lowe DG, Tai JTN, Sehl P, Jin H, Yang R, Predki PF, Rothberg BEG, Murtha MT, Roth ME, Shenoy
SG, Windemuth A, Simpson JW, Simons JF, Daley MP, Gold SA, McKenna MP, Hillian K, Went GT, & Rothberg JM.
1999. Gene expression analysis by transcript profiling coupled to a gene database query. Nature Biotechnology 17: 798803.
36. Miller MM, Gould BE, Joshi D, Bennett HPJ, James S, & Billiar RB. 1992. Reversed phase liquid chromatographic
purification and isolation of a radio-iodinated selective probe for mu opioid receptors in the brain. Journal of
Neuroscience Methods 41: 93-99.
37. Miller MM, Gould BE, & Nelson JF. 1989. Aging and long-term ovariectomy alter the cytoarchotecture of the
hypothalamic-preoptic area of the C57BL/6J mouse. Neurobiology of Aging 10: 683-690.
INVITED ORAL PRESENTATIONS-External

Developing a Curriculum in Cancer Survivorship for Primary Care Providers,
Frank H. Netter School of Medicine, Quinnipiac University, Hamden, CT
 Panelist: ‘GI Cancer Survivorship topics’
 Date: 09/11/2015

4th International Conference and Exhibition on Pathology (Pathology 2015), New Orleans, LA
 Title: ‘Determinants of EGFR, KRAS and p53 somatic mutations among early-stage, resected lung
adenocarcinomas’.
 Date: 07/13/2015

Albert Einstein College of Medicine MSTP Women’s Forum, The Bronx, NY
 Title: ‘Ion Torrent sequencing in resectable solid tumor prognosis’.
 Date: 05/20/2015
Bonnie E. Gould Rothberg, MD, PhD, MPH
9
5/4/2017

Brigham Young University Department of Bioinformatics, Provo, UT
 Title: ‘NGS-based ‘omics approach to the epidemiology of resectable solid tumor outcomes’.
 Date: 02/19/2015

2014 World TSC Conference, Washington, DC
 Title: ‘The Yale Lung and GI Cancer Biorepositories: Biospecimen best practices, robust clinical annotations
and applications for TSC’.
 Date: 07/04/2014

New York University Department of Dermatology, New York, NY
 Title: ‘Molecular and lifestyle determinants of Stage II/III cutaneous melanoma prognosis’.
 Date: 05/16/2013

Third North American Congress of Epidemiology, Montreal, Canada
 Title: ‘Sources of bias and misclassification in assessing protein expression by quantitative
immunohistochemistry’.
 Date: 06/22/2011

4th Melanoma & Skin Centres Meeting/7th International Melanoma Research Congress, Sydney, Australia
 Title: ‘Tissue Biomarkers for Melanoma Prognosis in 2010’.
 Date: 11/04/2010

Pharmacogenetics and Pharmacogenomics-Pasteur Institute Euroconferences, Paris, France.
 Title: ‘Pharmacogenomics and Pharmacogenetics at CuraGen Corporation, An Integrated Approach’.
 Date: 10/12/2000.

2nd International New Technologies to Increase Drug Candidate Survivability, Philadelphia, PA.
 Title: ‘The use of GeneCalling, a comprehensive differential mRNA expression technology for identifying
surrogate markers of drug toxicity and efficacy: an effective method for lead optimization and compound
triage’.
 Date: 9/11/2000.

Pharmacogenomics, SNP’s and Genetic Patenting, Newark, NJ.
 Title: ‘Using a comprehensive differential mRNA expression technology for identifying surrogate markers of
drug toxicity and efficacy-an effective method for lead optimization and compound triage’.
 Date: 06/01/2000.

Pharmacogenomics Europe, Amsterdam, The Netherlands.
 Title: ‘The use of GeneCalling, a comprehensive differential mRNA expression technology for identifying
surrogate markers of drug toxicity and efficacy: an effective method for lead optimization and compound
triage’.
 Date: 05/18/2000.

Discovery 2000-Emerging Strategies for Drug Discovery, San Diego, CA.
 Title: ‘Expression-based drug response profiling in rat brain’.
 Date: 04/11/2000.

2nd Annual Conference on Predictive Toxicology in Drug Discovery, New Orleans, LA.
 Title: ‘The use of GeneCalling, a comprehensive differential mRNA expression technology, as an effective
method for lead optimization and candidate triage’.
 Date: 11/10/1999.

Application of Genomics to Animal Models for Pharmaceutical Studies: Mice and Rats, Boston, MA.
 Title: ‘Application of genomics to animal models: pharmacogenomics and positional expression cloning’.
 Date: 10/20/1999.
Bonnie E. Gould Rothberg, MD, PhD, MPH
10
5/4/2017

Drug Discovery Technology 1999, Boston, MA.
 Title: ‘The use of GeneCalling: a comprehensive differential mRNA expression technology as an effective
method for pharmacogenomic analysis of candidate drug activity and toxicity’.
 Date: 08/16/1999.

Smarter Lead Optimization-Easing the Bottleneck, San Diego, CA.
 Title: ‘The use of GeneCalling, a comprehensive differential mRNA expression technology, as an effective
method for lead optimization and candidate triage’.
 Date: 03/17/1999.

Pharmacogenomics: Commercial Developments and Practical Applications, Philadelphia, PA.
 Title: ‘Pharmacogenomics at CuraGen Corporation: Triaging drug pipelines by comprehensive, gene-based
mode of action and toxicity screening’.
 Date: 08/17/1998.
PATENT APPLICATIONS
Issued Patents
1.
DiPippo VA, Ramesh TM, Gerwien RW, & Gould Rothberg BE. 1999 (issued 02/08/2005). Method of identifying
toxic agents using NSAID-induced differential gene expression in liver; US patent # 6,852,845
2.
Gould Rothberg BE. 1998 (issued 06/15/2004). Method of identifying a psychotropic agent using differential gene
expression. WO00/37685; US patent # 6,750,012
3.
Gould Rothberg BE. 1999 (issued 09/16/2003). G-protein coupled receptor-encoding nucleic acids. WO64941; US
patent # 6,620,615.
4.
Gould Rothberg BE. 1998 (issued 04/22/2003). Compositions and methods relating to the peroxisomal proliferator
activated receptor- mediated pathway. WO0029846. US patent # 6,551,812.
5.
Gould Rothberg BE, & Rastelli L. 1999 (issued 08/20/2002). Method of classifying a thyroid carcinoma using
differential gene expression. WO00/63498; US patent # 6,436,642.
Published PCT Applications
1.
Rimm DL, Moeder CM, & Gould Rothberg BE. 2008 (filed). Methods for differential diagnosis of melanocytic lesions.
WO2009/005816.
2.
Gould Rothberg BE, & Pena C. 2001 (filed). Novel fibroblast growth factor receptor 1-alpha IIIb and fibroblast growth
factor receptor-1-beta IIIb-like proteins and nucleic acids encoding the same.
3.
Gerwien RW, & Gould Rothberg BE. 2000 (filed). System and method for analyzing expression data for generating
predictive markers.
4.
Gould Rothberg BE, DiPippo VA, & Daniels KK. 2000 (filed). Method of identifying toxic agents using differential
gene expression (Fenfluramine/Dexfenfluramine). WO01/63279.
5.
Rastelli L, Murphey R, and Gould Rothberg BE. 1999 (filed). Methods of diagnosis and treatment related to tuberous
sclerosis complex and certain cancers.
6.
Gould Rothberg BE. 1999 (filed). Method of identifying ligands for the peroxisome proliferator activated receptor
gamma using differential gene expression (Troglitazone mechanism of action across 3 rat strains).
7.
Gould Rothberg BE, & V.A. DiPippo. 1999 (filed). Method of identifying toxic agents using differential gene
expression (Troglitazone). WO0063465.
8.
Gould Rothberg BE, V.A. DiPippo, L. Milroy & K.K. Daniels. 1999 (filed). Method of identifying toxic agents using
differential gene expression (Acetominophen). WO02609.
Bonnie E. Gould Rothberg, MD, PhD, MPH
11
5/4/2017
9.
Gould Rothberg BE. 1998 (filed). Methods for identifying ligands for the peroxisome proliferator activated receptor
gamma using differential gene expression. WO0065091.
THESES
1.
Gould Rothberg BE. 2009. Molecular prognostic markers in cutaneous melanoma. Doctor of Philosophy Thesis,
Department of Epidemiology and Public Health, Graduate School of Arts and Sciences, Yale University, New Haven,
Connecticut.
2.
Gould Rothberg BE. 2005. Tuberous Sclerosis natural history: The PLANETS cohort. Masters of Public Health
Thesis, Section of Chronic Disease Epidemiology, Department of Epidemiology and Public Health, Yale University,
New Haven, Connecticut.
3.
Gould BE. 1994. WANTED: ONE GOOD DOCTOR. Depictions of the good physician in twelve American novels,
1859-1925. Medical School Thesis, Department of History of Medicine, Yale University, New Haven, Connecticut.
4.
Gould BE. 1990. Levels and organization of DNA restriction map variation across the third chromosome of a single
field population of Drosophila melanogaster. Undergraduate Honors Thesis, Division of Biological Sciences, Section of
Genetics and Development. Cornell University, Ithaca, New York.
ABSTRACTS/POSTERS
1.
Majumder S, Taylor WR, Yab TC, Berger CK, Dukek BA, Cao X, Foote PH, Mahoney DW, Aslanian HR, Doyle LA,
Farrell JJ, Fisher WE, Lee LS, Lee YN, Park W, Gould Rothberg BE, Salem RR, Simeone DM, Urs S, VanBuren G,
Smyrk TC, Allawi HT, Lidgard GP, Raimondo M, Chari ST, Kisiel JB, Topazian MD, Ahlquist DA. 2017. Novel DNA
methylation markers assayed from cyst fluid accurately detect advanced neoplasia in pancreatic cysts: A multicenter
study. Digestive Disease Week 2017. May 6th-9th, 2017. Chicago, IL. (PLATFORM PRESENTATION).
2.
Karakousis G, O’Donoghue C, Leong S, Gimotty P, Neuwirth M, Sinammon A, Dueck A, Pockaj B, White R,
Garberoglio C, Vezeridis M, Gould Rothberg B, Messina J, Sondak V, Han D, Kashani-Sabet M, Faries M and Zager J.
2017. Prognostic significance of microsatellitosis in patients with melanoma. 70th Society of Surgical Oncology Annual
Cancer Symposium. March 15th-18th, Seattle, WA.
3.
Gould Rothberg BE, Das R, Jackson LK, Lazowski H, Bai Y, O’Neill D, Roberts SH, Rothberg JM, Herbst RS, Kim
AW, Boffa D, Rimm DL, Detterbeck FC and Tanoue LT. 2016. The prognostic impact of EGFR, KRAS and TP53
somatic mutations in curatively resected early-stage lung adenocarcinomas. International Association for the Study of
Lung Cancer 17th World Conference on Lung Cancer. December 4th-7th, Vienna, Austria.
4.
Majumder S, Taylor WR, Yab TC, Berger CK, Mahoney DW, Aslanian HR, Farrell JJ, Fisher WE, Gould Rothberg
BE, Salem RR, Simeone DM, Van Buren G, Raimondo M, Chari ST, Kisiel JB, Topazian MD and Ahlquist DA. 2016.
Detection of advanced neoplasia in pancreatic cysts by assay of novel DNA methylation markers in cyst fluid: a
multicenter pilot study. American College of Gastroenterology 2016 Annual Scientific Meeting. October 14th-19th, Las
Vegas, NV. (PLATFORM PRESENTATION).
5.
Sasaki T, Das RK, Fu Y, Chen XS, Gould Rothberg BE, & Anderson KS. 2016. Biochemical and functional
characterization of mutagenic cytidine deaminase APOBEC3B. 81st Cold Spring Harbor Laboratory Symposium on
Quantitative Biology Targeting Cancer. June 1st-5th, Cold Spring Harbor, NY.
6.
Rubinstein J, Han G, Jackson L, Bulloch K, Ariyan S, Narayan D, Gould Rothberg B & Han D. 2016. Regression in
thin melanoma predicts for nodal recurrence after a negative sentinel lymph node biopsy. 69th Society of Surgical
Oncology Annual Cancer Symposium. March 2nd-5th, Boston MA.
7.
Bello D, Han G, Jackson L, Bulloch K, Ariyan S, Narayan D, Gould Rothberg B & Han D. 2016. Prognostic
significance of sentinel node status in patients with thick melanoma. 69th Society of Surgical Oncology Annual Cancer
Symposium. March 2nd-5th, Boston MA.
8.
Jackson LK, Bulloch Whitehall KJ, Narayan D, Ariyan S, & Gould Rothberg BE. 2016. Body mass index further
accentuates the observed female survival benefit among a single-institution cohort of cutaneous melanomas >1 mm thick
following wide-local excision and sentinel lymph node biopsy. ASCO Cancer Survivorship Symposium: Advancing care
and research. January 15th-16th, San Francisco, CA.
Bonnie E. Gould Rothberg, MD, PhD, MPH
12
5/4/2017
9.
Gould Rothberg BE, Lazowski HM, Jackson LK, Law JN, Durrant MG, Roberts SH, Rothberg JM, Dyer MD,
Detterbeck FC, Boffa DJ, Kim AW, Herbst RS, Rimm DL & Tanoue LT. 2015. Determinants of EGFR, KRAS and p53
somatic mutations among resected early-stage lung adenocarcinomas. American College of Physicians Connecticut
Chapter Annual Meeting. October 30th, Southington, CT.
10. Lazowski H, Jackson LK, Law JN, Roberts SH, Rothberg JM, Detterbeck FC, Boffa DJ, Kim AW, Herbst RS, Rimm
DL, Tanoue LT & Gould Rothberg BE. 2015. Determinants of EGFR, KRAS and p53 somatic mutations among
resected early-stage lung adenocarcinomas. Lung Cancer SPORE Workshop. June 15th-16th, Shady Grove, MD.
(PLATFORM PRESENTATION).
11. Cecchini M, Gould Rothberg BE, Detterbeck FC & Tanoue LT. 2015. Multifocal lung cancer: Clinical and pathologic
description of a lung cancer subgroup (A3590). American Thoracic Society 2015 Annual Meeting. May 15th-20th,
Denver, CO.
12. Gould Rothberg BE, Deminie C, Lazowski H, Gibson J, Cha C, Lacy J, Hochster H, & Salem R. 2015. The Yale
Gastrointestinal Cancer Biorepository: A comprehensive biospecimen and data resource for studying determinants in
pancreatic ductal adenocarcinoma prognosis following curative-intent pancreaticoduodenectomy. 2015 Gastrointestinal
Cancers Symposium: Bridging Cancer Biology to Clinical GI Oncology. January 15th-17th, San Francisco, CA.
13. Srisuttiyakorn C, Bosenberg M, Gould Rothberg BE, Bulloch K & Galan A. 2014. Multinucleated giant cells in
primary cutaneous melanoma. 17th Joint Meeting of the International Society of Dermatopathology. March 19th-20th,
Denver, CO. (PLATFORM PRESENTATION).
14. Maron SB, Gould Rothberg B, Otremba M, Judson B & Morgensztern D. 2013. Role of adjuvant radiation in patients
with squamous cell carcinomas of the oral cavity. American Society of Clinical Oncology Annual Meeting 2013. May
31st-June 4th, Chicago, IL.
15. Zhang Y, Gould Rothberg BE & Morgensztern D. 2013. Survival and cause of death in patients with refractory anemia.
American Society of Clinical Oncology Annual Meeting 2013. May 31st-June 4th, Chicago, IL. (PLATFORM
PRESENTATION).
16. Gould Rothberg BE, Bulloch KJ, Fine JA, Barnhill RL & Berwick M. 2012. Lifestyle behaviors in localized cutaneous
melanoma prognosis. Society of Melanoma Research 2012 Congress. November 8th-11th, Hollywood, CA.
17. Gould Rothberg BE, Lewis H, Herbst RS, Detterbeck FC, Mayne ST, Rimm DL & Tanoue LT. 2012. The Yale Lung
Cancer Biorepository: Merging best practices in biospecimen science and clinic-epidemiologic annotation enables
analysis of gene-environment interactions affecting lung cancer prognosis. Advancing Cancer Research Through
Biospecimen Science. February 22nd-23rd, Bethesda, MD.
18. Gould Rothberg BE, Viray H, Madan A, & Rimm DL. 2011. Immunohistochemical analysis of LAM markers describes
subpopulations of pulmonary LAM patients. The LAM Foundation 2011 International Research Conference. April 9th10th, Cincinnati, OH. (PLATFORM PRESENTATION).
19. Gould Rothberg BE, Viray H, Madan A, & Rimm DL. 2011. Immunohistochemical analysis of
lymphangioleiomyomatosis (LAM) markers across a large series of LAM and angiomyolipoma patients. LAM/TSC
Seminar Series 2011 Live/Virtual Poster Session Competition. March 24th, Boston, MA. (AWARDED 3rd PRIZE)
20. Gould Rothberg BE, Berger AJ, Molinaro AM, Subtil A, Krauthammer MO, Bradley WR, Ariyan S, Halaban R,
Kluger HM, & Rimm DL. 2008. Identification of a melanoma prognostic model using tissue microarrays and genetic
algorithms (Abstract #5566). American Association of Cancer Research Annual Meeting 2008. April 12th-16th, San
Diego, CA.
21. Gould Rothberg BE, Bracken MB, & Claus EB. 2005. “Patients Learning About the Natural Evolution of Tuberous
Sclerosis” (PLANETS) Study. I: Description of the cohort and results for kidney angiomyolipomas (Abstract #737). The
American Society for Human Genetics 55th Annual Meeting. October 25th-29th, Salt Lake City, UT.
22. Dharnidharka VR, Grooms MC, & Gould Rothberg BE. 2005. Rapid Growth of a Kidney Angiomyolipoma Following
Initiation of Oral Contraceptive Therapy (Abstract #3904). Journal of the American Society of Nephrology Supplement.
Bonnie E. Gould Rothberg, MD, PhD, MPH
13
5/4/2017
23. Gould Rothberg BE, Bracken MB, Claus EB. 2005. “Patients Learning About the Natural Evolution of Tuberous
Sclerosis” (PLANETS) Study. I: Description of the cohort and results for kidney angiomyolipomas. TSC/LAM
International Research Symposium. April 8-10th, Cincinnati, OH. (PLATFORM PRESENTATION)
24. Squillace RM, McCabe D, Lu H, Bento P, Chapoval A, Feschenko E, Gould Rothberg B, Rothberg J, Weiner MP.
2005. Microarray analysis to identify immunotherapeutic targets for LAM and TSC. TSC/LAM International Research
Symposium. April 8-10th, Cincinnati, OH.
25. Squillace R, Yu J, Caterina K, Rosado R, Wheeler J, Sobel S, Gould Rothberg BE, Rothberg JM, Henske EP, & Weiner
MP. 2004. Expression analysis: AML tissues and cell lines. Tuberous Sclerosis Association International Research
Conference. Cambridge, UK.
26. Squillace R, Yu J, Takacs S, Rosado R, Wheeler J, Sobel S, Gould Rothberg BE, Rothberg J, Henske E, & Weiner MP.
2004. Immortalization of human Tsc2 null AML cells. 2004 Rare lung disease conference. Cinncinnati, OH.
27. Gould Rothberg BE. 2003. Cell-based in vitro drug screening to identify novel lead compounds useful in treating the
clinical manifestations of Tuberous Sclerosis. TSC genes-novel players in the growth regulation network. Royal Society
of Medicine, London, UK. (PLATFORM PRESENTATION)
28. Hinz W, Chen J, Lei J, Wheeler JC, Rothberg JM & Gould Rothberg BE. 2002. Virtual library screening of available
compound libraries – lead discovery: finding the needle in the haystack. New Perspectives in Tuberous Sclerosis
Complex. Chantilly, VA.
29. Wheeler JC, Squillace R, Zlotoff D, Schwartz E, Hinz W, Gould Rothberg BE, & Rothberg JM. 2002. Cell-based
screening for compounds to treat Tuberous Sclerosis. New Perspectives in Tuberous Sclerosis Complex. Chantilly, VA.
30. Onda H, Crino PB, Zhang H, Murphey RD, Rastelli L, Gould Rothberg BE, & Kwiatkowski DJ. 2002. TSC2 null
murine neuroepithelial cells are a model for human tuber giant cells and show activation of an mTOR pathway. New
Perspectives in Tuberous Sclerosis Complex. Chantilly, VA.
31. Daniels KK, DiPippo VA, Murphey R, & Gould Rothberg BE. 2000. Pharmacogenomic analysis of cardiotoxic
serotonin-modulating agents utilizing GeneCalling, a high throughput method of differential gene expression. American
Association of Pharmaceutical Sciences Annual Meeting. Indianapolis, IN.
32. DiPippo VA, Murphey RD, & Gould Rothberg BE. 2000. In vivo dosing and use of differential gene expression to
determine troglitazone’s pharmacogenomic and toxicogenomic effects in rat liver. American Association of
Pharmaceutical Sciences Annual Meeting. Indianapolis, IN.
33. Ramesh TM, DiPippo VA, Murphey RD, Caprio SJ & Gould Rothberg BE. 2000. Expression pharmacogenomic
profiling of nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Keystone 2000: Fulfilling the promises of
genomics research. Taos, NM.
34. Bader JS, & Gould Rothberg BE. 1999. Cancer and Pharmacogenomics. RECOMB 99-Third Annual International
Conference on Computational Molecular Biology. Lyon, France.
35. Mishra VS, Novak EK, Holt S, Rothberg BE, Swank RT, & Kingsmore SF. 1997. Positional cloning of the mouse
mutation muted (mu). 11th International Mouse Genome Conference. St. Petersburg, FL.
36. Detter JC, Novak EK, McMurtie EB, Mishra VS, Rothberg BE, Swank RT, & Kingsmore SF. 1997. Positional cloning
of the mouse mutation gunmetal, an animal model for platelet storage pool deficiency. 11th International Mouse Genome
Conference. St. Petersburg, FL.
37. Mishra VS, Nguyen QA, Novak EK, Rusiniak ME, Hofig A, Holt S, Rothberg BE, Swank RT, & Kingsmore SF. 1997.
Positional cloning of the mouse mutation sandy (sdy). 11th International Mouse Genome Conference. St. Petersburg, FL.
38. Gould BE. Williams M, & Maizels N. 1992. LR-1, a B-cell specific lipopolysaccharide-responsive factor, bends DNA.
Yale School of Medicine Research Day. New Haven, CT.
Bonnie E. Gould Rothberg, MD, PhD, MPH
14
5/4/2017
39. Joshi D, Gould BE, & Miller MM. 1991. In vitro labelling of 125I-FK in the hypothalamic-preoptic area of the female
C57BL/6J mouse. Third IBRO World Congress of Neuroscience. Montreal, Canada.
INVITED ORAL PRESENTATIONS-Internal
Yale University (1994-1995; 2011-present)
1. Smilow Cancer Center 5th Anniversary Symposium; Gastrointestinal Cancer Program Representative
 Title: ‘Whole-exome sequencing of pancreatic neuroendocrine tumors (PanNETs): New targets and therapeutic
possibilities’.
 Date: 09/11/2015
2.
Medical Oncology Research in Progress
 Title: ‘Next-generation sequencing-based approach towards resectable solid tumor prognosis’.
 Date: 02/27/2015
3.
Internal Medicine Residency Program Lunchtime Lecture Series
 Title: ‘Radiogenomics of lung adenocarcinoma: Identifying radiographic correlates of molecular phenotypes’.
 Date: 05/20/2014
4.
Lung Cancer Translational Research Seminar
 Title: ‘Radiogenomics of lung adenocarcinoma: Identifying radiographic correlates of molecular phenotypes’.
 Date: 05/14/2014
5.
Medical Oncology Research In Progress
 Title: ‘Determinants of locoregional melanoma prognosis…and other stories’.
 Date: 02/21/2014
6.
Yale SPORE in Skin Cancer Research in Progress
 Title: ‘Tumor, germline and lifestyle determinants of long-term survival in Stage II/III cutaneous melanoma’.
 Date: 04/26/2013
7.
Medical Oncology Research In Progress
 Title: ‘Tumor, germline and lifestyle determinants of long-term survival in Stage II/III cutaneous melanoma’.
 Date: 02/15/2013
8.
Department of Pathology Special Seminar
 Title: ‘The Yale Lung and GI Cancer Biorepositories/Differential protein expression across a large series of
angiomyolipomas’.
 Date: 12/10/2012
9.
Cancer Center Grand Rounds
 Title: ‘The Yale Lung and GI Cancer Biorepositories: Enabling translational research through merging best
practices in biospecimen science and clinico-epidemiologic annotation’.
 Date: 12/04/2012
10. Internal Medicine Residency Program Lunchtime Lecture Series
 Title: ‘The Yale Lung Cancer Biorepository: A model for prospective, case-based cancer biospecimen
collection and annotation’.
 Date: 04/05/2012
11. Medical Oncology Research In Progress
 Title: ‘Determinants of long-term cancer survivorship when current standard-of-care best practices result in
~50% 5-year survival’.
 Date: 02/29/2012
Bonnie E. Gould Rothberg, MD, PhD, MPH
15
5/4/2017
12. Cancer Prevention and Control Research Program Seminar Series
 Title: ‘The Yale Lung Cancer Biorepository – A model for prospective, case-based cancer biospecimen
collection and annotation’.
 Date: 12/14/2011
13. Program for Humanities in Medicine.
 Title: 'Wanted: One Good Doctor'.
 Date: 01/19/1995.
14. Beaumont Club/Nathan Smith Club.
 Title: 'Wanted: One Good Doctor'.
 Date: 04/15/1994.
TEACHING EXPERIENCE
Graduate/Medical School Course Leader/co-Leader (Yale University Schools of Medicine & Public Health)
 Chronic Disease Epidemiology 617b: Developing a Research Protocol.
Spring 2013
-Course co-Leader
-Co-led all lectures and held semester-long weekly office hours
 Pharmacology 501b: Introduction to Pharmacology
Fall 2012
-Workshop co-Leader
-Coordinated and led 6-workshop series on Cancer Therapeutics
Guest Lectureships – Yale University School of Public Health Master’s and Doctoral-level Classes
 “Measurement Issues Associated with Mortality Outcomes”
- In: Chronic Disease Epidemiology 523b: Measurement Issues in Chronic Disease Epidemiology
- 90-minute lecture presented annually.
Spring 2007-14
 “Introduction to cancer biology and pathology”
-In: Chronic Disease Epidemiology 532b: Cancer Epidemiology
-90-minute lecture given:
Spring 2013
 “SAS Programming Basics: Parts 1, 2 and 3”
- In: Biostatistics 505a: Introduction to Statistical Thinking I.
- 2 1-hour lectures presented annually:
Fall 2005-08
Graduate Teaching Fellow – Yale University School of Public Health Master’s and Doctoral-level Classes
 Chronic Disease Epidemiology 619a: Advanced Epidemiologic Research Methods
- Holding weekly discussion sections and office hours
Fall 2007
- Preparing and delivering 2 course lectures
- Grading homework assignments
 Chronic Disease Epidemiology 521b: The Epidemiology of Selected Common Chronic Diseases
- Preparing and delivering 7 1-hour course lectures
Spring 2007
- Holding regular office hours and facilitating lecture-style review sessions
 Chronic Disease Epidemiology 630a: Molecular Epidemiology in Chronic Diseases
- Preparing and delivering 2 course lectures
Fall 2006
- Preparing the final exam
- Grading oral presentations and the final exam
- Holding regular weekly office hours and lecture-style review sessions
 Chronic Disease Epidemiology 523b: Measurement Issues in Chronic Disease Epidemiology
- Preparing and delivering 1 course lecture
Spring 2006
- Grading homework assignments (4 per semester; 40 students enrolled)
- Holding twice-weekly office hours and lecture-style review sessions
 Chronic Disease Epidemiology 517a: Developing a Research Protocol
Fall 2005
-Preparing and delivering selected course lectures
-Grading weekly homework assignments (40 students enrolled)
-Holding twice-weekly office hours
Bonnie E. Gould Rothberg, MD, PhD, MPH
16
5/4/2017

Biostatistics 505a: Introduction to Statistical Thinking I.
-Preparing and delivering selected course lectures
-Facilitating 4 SAS computer laboratory sessions per week, 15 students per session
-Holding twice-weekly office hours
-Grading homework problem sets
Fall 2004
Mentorship Activities
Dissertation Committee Member
Pok Fai Wang (2016-present)
David Rimm, PI
MPH Student Internship Mentor
Joseph Xavier Jeyanth Jenkins Fernandez (2016)
BE Gould Rothberg, PI
Past and Current Trainees
Undergraduates
Bonnie Hawkins (Smith College ‘15)
Jeffrey N. Law (Brigham Young U. ‘15)
Matt G. Durrant (Brigham Young U. ‘16)
Cleo Kyriakides (Cornell U. ’20)
Michelle Boisvert (UC Berkley ’19)
Serena Tharakan (Yale U. ’18)
Post-Baccalaureate
Jennifer Nadelmann (BS, Yale U. ‘13)
Laura K. Jackson (BS, UCONN, ‘14)
Sophia H. Roberts (BS, Yale U., ‘14)
MPH Students
Kaleigh J. Bulloch (MPH, YSPH, ‘13)
Post-Doctoral Associates
Rahul Das (PhD, Rice U., ‘09)
Jennifer Cantley (PhD, UMass)
Sandeep Singh (MBBS, )
Bonnie E. Gould Rothberg, MD, PhD, MPH
Training Period
Subsequent Position
Summers 2012 & 2013
06/2014-08/2015
06/2015-03/2016
Summer 2016
Summer 2016
Summer 2017
Yale School of Medicine (2019)
Virginia Tech. Bioinformatics PhD Student
Bioinformatics PhD student
Mount Sinai School of Medicine (2022)
06/2013-07/2014
06/2014-05/2016
06/2014-05/2016
Albert Einstein College of Medicine (2018)
U. Washington Genetics PhD Student
Ohio State School of Medicine (2020)
05/2012-08/2014
Clinical Research Associate in Pharma
09/2015-current
01/2017-current
06/2017-current
17
5/4/2017